| Ytd | -9.10% | |
| 1y | 51.86% |
| Open | 11.89 | Prev Close | 11.98 | Low | 11.89 | High | 13.68 | Mkt Cap | 676.72M |
| Vol | 4.44M | Avg Vol | 1.73M | EPS | -5.60 | P/E | N/A | Forward P/E | -6.83 |
| Beta | 1.23 | Short Ratio | 6.02 | Inst. Own | 92.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 8.21 | 200-d Avg | 10.39 | 1yr Est | 37.64 |
RGNX News
New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Societ
New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Societ
REGENXBIO upgraded to 'Strong Buy' on FDA's course reversal for rare disease therapies, notably impa
Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D
HC Wainwright & Co. analyst Yi Chen reiterates Regenxbio (NASDAQ:RGNX) with a Buy and maintai
Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator
Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the pr
Leerink Partners analyst Mani Foroohar maintains Regenxbio (NASDAQ:RGNX) with a Outperform and ra
FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy ap
REGENXBIO Inc. (NASDAQ:RGNX) today announced it has aligned with the U.S. Food and Drug Administrati
SAGT: 124% | Sagtec Global CEO's 1.5M Share Acquisition And $1.56M Private Placement Coincide Wi
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers t
B of A Securities analyst Geoff Meacham maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers t
Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowers the pri
REGENXBIO reports positive Phase 3 Duchenne trial data as RGX-202 met its primary endpoint with stro
US stocks up, Dow gains 250+ pts. Tech sector up 0.8%, healthcare down 0.3%. Retail sales rise 0.5%
REGENXBIO Inc. (NASDAQ:RGNX) announced positive topline and interim functional data from the pivotal
Nancy Pelosi Stock Tracker highlighted Claude AI's Denali Therapeutics earnings bet, which targe
Denali Therapeutic snags FDA accelerated approval for Avlayah for Hunter syndrome, analyst flags str
Regenxbio releases new Duchenne trial data showing improved motor function and stable heart measures
Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory
FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers t
Morgan Stanley analyst Judah Frommer maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowe
Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.30) per share which missed the analyst cons
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers t
Goldman Sachs analyst Paul Choi maintains Regenxbio (NASDAQ:RGNX) with a Neutral and lowers the p
Morgan Stanley analyst Judah Frommer maintains Regenxbio (NASDAQ:RGNX) with a Overweight and lowe
REGENXBIO shares fall after the FDA issues a response letter on its Hunter syndrome gene therapy, ra
